Philipp Hadwiger

TL;DR: The data reported here provide background to successfully address challenges associated with the manufacture of siRNAs and other nucleic acid therapeutics such as aptamers, spiegelmers, and decoy and antisense oligonucleotides.

TL;DR: Derivatives of d-xylose and d-glucose were synthesized and used as substrates of the NAD(P)H-dependent aldehyde reduction catalysed by aldose reductases isolated from the yeasts Candida tenuis, C. intermedia and Cryptococcus flavus and steady-state kinetic analysis showed that they were reduced with up to 3000-fold increased catalytic efficiencies.

TL;DR: The introduction of ribozymes targeting the FAPP2 gene in colon carcinoma cells induced their apoptosis in the presence of Fas agonistic antibody, and by quantitative PCR it was shown that a siRNA specific to F APP2, but not a randomized siRNA control, reduced FAPP 2 gene expression in tumor cells.

TL;DR: In this paper, a drug for inhibiting the expression of a target gene was described, with the drug being present in at least one administration unit which contains a double strand ribonucleic acid suitable for inhibition through RNA interference, in an amount allowing a dosage of less than 5 mg per kilogram of bodyweight per day.